Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

被引：0

作者：

Moldaver, Daniel ^{[1
]}

Anderson, Seth ^{[2
]}

Bracher, Marguerite ^{[3
]}

Levy, Roger A. ^{[4
]}

Quasny, Holly A. ^{[5
]}

Wood, Robert ^{[6
]}

Wild, Rosie ^{[6
]}

Cusmano, Alexandra ^{[6
]}

Rottier, Elke ^{[6
]}

机构：

[1] GlaxoSmithKline, Value Evidence & Outcomes, Toronto, ON, Canada

[2] GlaxoSmithKline, Value Evidence & Outcomes, Collegeville, PA USA

[3] GlaxoSmithKline, Value Evidence & Outcomes, Stevenage, Herts, England

[4] GlaxoSmithKline, Global Med Affairs, Collegeville, PA USA

[5] GlaxoSmithKline, Res & Dev, Durham, NC USA

[6] Adelphi Real World, Real World Evidence, Bollington, Cheshire, England

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0587

引用

页码：1159 / 1161

页数：3

共 1 条